Palvella Therapeutics (NASDAQ:PVLA) Raised to Strong-Buy at Jones Trading

Palvella Therapeutics (NASDAQ:PVLA) was upgraded by stock analysts at Jones Trading to a “strong-buy” rating in a note issued to investors on Monday,Zacks.com reports.

PVLA has been the topic of a number of other research reports. Canaccord Genuity Group reissued a “buy” rating and issued a $39.00 price objective on shares of Palvella Therapeutics in a report on Wednesday, February 26th. HC Wainwright reiterated a “buy” rating and set a $38.00 price target on shares of Palvella Therapeutics in a research note on Tuesday, February 11th. TD Cowen initiated coverage on Palvella Therapeutics in a research note on Wednesday, February 5th. They issued a “buy” rating and a $44.00 price objective for the company. Scotiabank began coverage on Palvella Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $50.00 target price on the stock. Finally, Cantor Fitzgerald initiated coverage on Palvella Therapeutics in a research report on Wednesday, December 18th. They issued an “overweight” rating for the company. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $43.20.

Palvella Therapeutics Price Performance

Shares of NASDAQ:PVLA opened at $27.27 on Monday. The stock has a 50-day moving average price of $19.36. The stock has a market capitalization of $306.00 million, a PE ratio of -2.25 and a beta of 0.54. Palvella Therapeutics has a 52-week low of $6.20 and a 52-week high of $29.27.

Institutional Investors Weigh In On Palvella Therapeutics

A number of institutional investors have recently bought and sold shares of the business. BML Capital Management LLC bought a new position in shares of Palvella Therapeutics in the fourth quarter worth about $506,000. Frazier Life Sciences Management L.P. bought a new position in Palvella Therapeutics in the 4th quarter worth approximately $7,847,000. Cresset Asset Management LLC purchased a new stake in Palvella Therapeutics during the 4th quarter valued at approximately $251,000. Suvretta Capital Management LLC purchased a new stake in Palvella Therapeutics during the 4th quarter valued at approximately $8,574,000. Finally, DAFNA Capital Management LLC bought a new stake in shares of Palvella Therapeutics during the fourth quarter valued at approximately $857,000. Hedge funds and other institutional investors own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.